IL-17F: A Key Inflammatory Driver and Its Emerging Role in Therapy

I. Biological Characteristics and Functions of IL-17F

IL-17F is a key member of the interleukin-17 (IL-17) cytokine family, sharing approximately 50% amino acid sequence homology with IL-17A. Both cytokines bind to a common receptor complex (typically composed of IL-17RA and IL-17RC subunits), activating downstream signaling pathways such as NF-κB and MAPK, which induce epithelial cells, fibroblasts, and other cell types to produce various pro-inflammatory cytokines (e.g., IL-6, IL-8, GM-CSF), antimicrobial peptides, and chemokines. While IL-17A and IL-17F exhibit functional overlap, they also display distinct characteristics. They work synergistically to recruit and activate immune cells like neutrophils, playing central roles in host defense and the pathogenesis of various autoimmune/inflammatory diseases. Recent structural biology studies have further revealed that IL-17F can form homodimeric complexes with IL-17RC, enabling partial signal transduction independent of IL-17RA, expanding our understanding of the complexity of IL-17 family signaling.

II. Validation of IL-17F as a Therapeutic Target in Autoimmune Diseases

Given the pivotal role of the IL-17 pathway in chronic inflammation, targeting this pathway has become a key strategy for treating autoimmune diseases. Currently approved biologics targeting IL-17A or IL-17 receptors have demonstrated remarkable efficacy in conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, validating the therapeutic potential of this pathway. However, research suggests that simultaneous neutralization of both IL-17A and IL-17F may yield superior therapeutic outcomes. Preclinical data indicate that dual blockade of IL-17A and IL-17F more effectively suppresses the expression of inflammation-related genes and immune cell migration compared to targeting IL-17A alone, highlighting the IL-17F protein as an independent or synergistic player in disease pathogenesis. This scientific insight has directly driven the development of next-generation dual-neutralizing antibodies, with pivotal Phase III clinical trials in psoriasis treatment showing better skin clearance rates and sustained remission than existing therapies.

III. Application Value of IL-17F Protein as a Research Tool

In-depth exploration of IL-17F's biological functions and its role in disease mechanisms relies on high-quality recombinant protein tools. The IL-17F protein holds critical value across multiple research dimensions:

1. Signaling Mechanism Studies: Used for in vitro stimulation of target cells to investigate the signaling transduction characteristics, gene expression profile changes, and effector molecules induced by IL-17F alone or in synergy with IL-17A.

2. Receptor Interaction Analysis: Employed to elucidate the binding properties, affinity, and complex structures of IL-17F with receptors IL-17RA/IL-17RC, particularly studying its novel mechanism of forming homodimeric signaling complexes.

3. Drug Screening and Evaluation: Serves as a core target antigen for screening and assessing the activity, potency, and specificity of therapeutic candidates such as neutralizing antibodies and small-molecule inhibitors (e.g., distinguishing between inhibition of IL-17A and IL-17F).

4. Exploration of Novel Disease Models: Emerging research suggests that IL-17 signaling may participate in neural development and behavioral regulation. Using the IL-17F protein in such studies could help uncover its potential functions in neurological abnormalities or developmental disorders, providing a theoretical foundation for expanding therapeutic indications.

IV. Future Prospects: From Inflammatory Diseases to Broader Disease Spectra

Currently, therapies targeting the IL-17 pathway (including IL-17F) primarily focus on autoimmune diseases of the skin and joints. However, as fundamental research progresses, their therapeutic potential is expanding into broader disease areas. Beyond traditional inflammatory conditions like inflammatory bowel disease (IBD), recent findings on IL-17's role in the nervous system—particularly its influence on social behavior under specific conditions—have opened new perspectives for understanding neuro-immune interactions. These insights may offer novel intervention strategies for related neurodevelopmental disorders. In the future, refined analysis of the IL-17F protein and its signaling network will facilitate the development of more selective and effective targeting strategies, potentially extending therapeutic indications to currently unmet clinical needs and further unlocking its therapeutic potential.

V. Which Manufacturers Provide IL-17F Protein?

Nanjing U-Protein自主研发的 IL-17F Protein, Mouse (Catalog No.: UA040476) is a high-purity, high-activity recombinant mouse interleukin-17F (IL-17F) protein produced using a mammalian expression system, featuring spatial conformation and post-translational modifications consistent with the native protein. As a member of the IL-17 cytokine family, IL-17F is primarily produced by Th17 cells and plays a crucial role in host defense, mucosal immunity, and inflammatory diseases (e.g., psoriasis, asthma). This product has undergone rigorous validation for purity, stability, and biological activity, making it an essential tool for studying mouse models of inflammation and autoimmunity.

Professional Technical Support: We provide detailed product documentation, recommended protocols, storage guidelines, and expert consultation on IL-17F's role in mouse autoimmunity, inflammation, mucosal immunity, and drug development.

Nanjing U-Protein is committed to delivering high-quality core protein tools for immunology research, mouse disease modeling, and innovative drug development. For detailed technical specifications, activity validation data, or application inquiries regarding IL-17F Protein, Mouse (Catalog No.: UA040476), please feel free to contact us.